Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 44: 1666-1673, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cernacek, P.
Right arrow Articles by Levy, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cernacek, P.
Right arrow Articles by Levy, M.
Related Collections
Right arrow Drug Monitoring and Toxicology
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 1998;44:1666-1673.)
© 1998 American Association for Clinical Chemistry, Inc.

Drug Monitoring and Toxicology

Radioreceptor assay of an endothelin A receptor antagonist in plasma and urine

Peter Cernacek1,a, Luigi Franchi2, Jocelyn Dupuis1, Jean-Lucien Rouleau1, and Mortimer Levy2,3

1 Montreal Heart Institute, Department of Laboratory Medicine, 5000 Belanger Street East, Montreal, Quebec, H1T 1C8 Canada.
Departments of
2 Medicine and
3 Physiology, McGill University, Montreal, Quebec, H1T 1C8 Canada.
a Author for correspondence. Fax (514) 593-2577; e-mail jhunte{at}is.RVH.McGill.CA.

Orally active nonpeptide antagonists of endothelin (ET) receptors may prove beneficial in the treatment of cardiovascular and renal disease. The pharmacodynamics and pharmacokinetics of these drugs are not sufficiently known, and practical methods for their analysis have not been developed. We describe a simple, sensitive, and reproducible radioreceptor assay (RRA) for LU135252, a selective antagonist of the ETA receptor, using porcine aortic smooth muscle membranes as the acceptor and 125I-endothelin-1 as the ligand. With methanol extraction of plasma and urine samples, recovery of LU135252 ranged from 79% to 91% at 60–1000 nmol/L. The logit-log transformed calibration curves constructed with LU135252 added to plasma or to urine were linear (r = 0.993 ± 0.005, n = 11) in the range from 18.7 to 2400 nmol/L. The detection limit with plasma- and urine-based calibration curves was 19 nmol/L. The interassay coefficient of variation was 12.6% at 70 nmol/L (n = 9) and 6.5% at 590 nmol/L (n = 9). Endothelin-1 did not interfere in the RRA at pathophysiologically and clinically relevant concentrations [up to 15 pmol/L (40 pg/mL)]. When LU135252 was added to plasma, the signal was completely stable after storage for 1 week at 4 °C, although there was a modest loss of the signal after 24 h at room temperature. The practical performance of this RRA was then tested in plasma samples obtained from (a) rats after a single oral administration of LU135252, (b) from coronary-ligated rats chronically treated with LU135252, and (c) in plasma and urine samples obtained from dogs during intrarenal infusion of LU135252.




The following articles in journals at HighWire Press have cited this article:


Home page
 The Annals of PharmacotherapyHome page
B. J Epstein
Efficacy and Safety of Darusentan: A Novel Endothelin Receptor Antagonist
Ann. Pharmacother., July 1, 2008; 42(7): 1060 - 1069.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
B. Petersen, M. Deja, R. Bartholdy, B. Donaubauer, S. Laudi, R. C. E. Francis, W. Boemke, U. Kaisers, and T. Busch
Inhalation of the ETA receptor antagonist LU-135252 selectively attenuates hypoxic pulmonary vasoconstriction
Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2008; 294(2): R601 - R605.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
Q. T. Nguyen, P. Cernacek, M. G. Sirois, A. Calderone, N. Lapointe, D. J. Stewart, and J. L. Rouleau
Long-Term Effects of Nonselective Endothelin A and B Receptor Antagonism in Postinfarction Rat: Importance of Timing
Circulation, October 23, 2001; 104(17): 2075 - 2081.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
S. Babaei, P. Picard, A. Ravandi, J. C. Monge, T. C. Lee, P. Cernacek, and D. J. Stewart
Blockade of endothelin receptors markedly reduces atherosclerosis in LDL receptor deficient mice: role of endothelin in macrophage foam cell formation
Cardiovasc Res, October 1, 2000; 48(1): 158 - 167.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
K. AMANN, K. MÜNTER, S. WESSELS, J. WAGNER, V. BALAJEW, S. HERGENRÖDER, G. MALL, and E. RITZ
Endothelin A Receptor Blockade Prevents Capillary/Myocyte Mismatch in the Heart of Uremic Animals
J. Am. Soc. Nephrol., September 1, 2000; 11(9): 1702 - 1711.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.